Impact of myeloperoxidase-LDL interactions on enzyme activity and subsequent posttranslational oxidative modifications of apoB-100

Journal of Lipid Research

Volumn 55, Issue 4, 2014, Pages 747-757

  Delporte, Cédric ^a   Boudjeltia, Karim Zouaoui ^a   Noyon, Caroline ^a   Furtmüller, Paul G ^b   Nuyens, Vincent ^a   Slomianny, Marie Christine ^c   Madhoun, Philippe ^a   Desmet, Jean Marc ^a   Raynal, Pierre ^d   Dufour, Damien ^a   Koyani, Chintan N ^e   Reyé, Florence ^a   Rousseau, Alexandre ^a   Vanhaeverbeek, Michel ^a   Ducobu, Jean ^a   Michalski, Jean Claude ^c   Nève, Jean ^a   Vanhamme, Luc ^a   Obinger, Christian ^b   Malle, Ernst ^e   Van Antwerpen, Pierre ^a   more..

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^c UNIVERSITÉ DES SCIENCES ET TECHNOLOGIES DE LILLE   (France)

^d Centre Hospitalier Universitaire de Charleroi   (Belgium)

^e UNIVERSITY OF GRAZ   (Austria)

Author keywords

3 chlorotyrosine; Apolipoprotein B 100; Epitope mapping; Hypochlorous acid; Inflammation; Low density lipoprotein; Myeloperoxidase activity

Indexed keywords

APOLIPOPROTEIN B100; MYELOPEROXIDASE; APOB PROTEIN, HUMAN; HYDROGEN PEROXIDE; LOW DENSITY LIPOPROTEIN; PEPTIDE FRAGMENT; PEROXIDASE;

ARTICLE; CHLORINATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME METABOLISM; ENZYME MODIFICATION; ENZYME RELEASE; ENZYME STRUCTURE; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; AMINO ACID SEQUENCE; BLOOD; CASE CONTROL STUDY; CHEMISTRY; HYDROLYSIS; KIDNEY DISEASES; METABOLISM; MOLECULAR GENETICS; OXIDATION REDUCTION REACTION; RENAL REPLACEMENT THERAPY;

AMINO ACID SEQUENCE; APOLIPOPROTEIN B-100; CASE-CONTROL STUDIES; HUMANS; HYDROGEN PEROXIDE; HYDROLYSIS; KIDNEY DISEASES; LIPOPROTEINS, LDL; MOLECULAR SEQUENCE DATA; OXIDATION-REDUCTION; PEPTIDE FRAGMENTS; PEROXIDASE; PROTEIN PROCESSING, POST-TRANSLATIONAL; RENAL DIALYSIS;

EID: 84897462945     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M047449     Document Type: Article

References (54)

1. Klebanoff, S. J. 2005. Myeloperoxidase: friend and foe. J. Leukoc. Biol. 77: 598-625.
2. Arnhold, J., and J. Flemmig. 2010. Human myeloperoxidase in innate and acquired immunity. Arch. Biochem. Biophys. 500: 92-106.
3. Davies, M. J., C. L. Hawkins, D. I. Pattison, and M. D. Rees. 2008. Mammalian heme peroxidases: from molecular mechanisms to health implications. Antioxid. Redox Signal. 10: 1199-1234.
4. Hazell, L. J., L. Arnold, D. Flowers, G. Waeg, E. Malle, and R. Stocker. 1996. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J. Clin. Invest. 97: 1535-1544.
5. Malle, E., G. Waeg, R. Schreiber, E. F. Grone, W. Sattler, and H. J. Grone. 2000. Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur. J. Biochem. 267: 4495-4503.
6. Malle, E., T. Buch, and H. J. Grone. 2003. Myeloperoxidase in kidney disease. Kidney Int. 64: 1956-1967
7. Daugherty, A., J. L. Dunn, D. L. Rateri, and J. W. Heinecke. 1994. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94: 437-444.
8. Daugherty, A., and S. E. Roselaar. 1995. Lipoprotein oxidation as a mediator of atherogenesis: insights from pharmacological studies. Cardiovasc. Res. 29: 297-311.
9. Itabe, H. 2009. Oxidative modification of LDL: its pathological role in atherosclerosis. Clin. Rev. Allergy Immunol. 37: 4-11.
10. Yang, C. Y., Z. W. Gu, H. X. Yang, M. Yang, A. M. Gotto, Jr., and C. V. Smith. 1997. Oxidative modifications of apoB-100 by exposure of low density lipoproteins to HOCL in vitro. Free Radic. Biol. Med. 23: 82-89.
11. Moguilevsky, N., K. Zouaoui Boudjeltia, S. Babar, P. Delree, I. Legssyer, Y. Carpentier, M. Vanhaeverbeek, and J. Ducobu. 2004. Monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions. Biochem. Biophys. Res. Commun. 323: 1223-1228.
12. Hazen, S. L., and J. W. Heinecke. 1997. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest. 99: 2075-2081.
13. Malle, E., G. Marsche, J. Arnhold, and M. J. Davies. 2006. Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim. Biophys. Acta. 1761: 392-415.
14. Marsche, G., B. Weigle, W. Sattler, and E. Malle. 2007. Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochloritemodified low-density lipoprotein. FASEB J. 21: 3075-3082.
15. Marsche, G., R. Zimmermann, S. Horiuchi, N. N. Tandon, W. Sattler, and E. Malle. 2003. Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein. J. Biol. Chem. 278: 47562-47570.
16. Hazell, L. J., and R. Stocker. 1993. Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. Biochem. J. 290: 165-172.
17. Boudjeltia, K. Z., I. Legssyer, P. Van Antwerpen, R. L. Kisoka, S. Babar, N. Moguilevsky, P. Delree, J. Ducobu, C. Remacle, M. Vanhaeverbeek, et al. 2006. Triggering of inflammatory response by myeloperoxidase-oxidized LDL. Biochem. Cell Biol. 84: 805-812.
18. Calay, D., A. Rousseau, L. Mattart, V. Nuyens, C. Delporte, P. Van Antwerpen, N. Moguilevsky, T. Arnould, K. Z. Boudjeltia, and M. Raes. 2010. Copper and myeloperoxidase-modified LDLs activate Nrf2 through different pathways of ROS production in macrophages. Antioxid. Redox Signal. 13: 1491-1502.
19. Hazen, S. L., J. R. Crowley, D. M. Mueller, and J. W. Heinecke. 1997. Mass spectrometric quantification of 3-chlorotyrosine in human tissues with attomole sensitivity: a sensitive and specific marker for myeloperoxidase- catalyzed chlorination at sites of inflammation.Free Radic. Biol. Med. 23: 909-916.
20. Zheng, L., B. Nukuna, M. L. Brennan, M. Sun, M. Goormastic, M. Settle, D. Schmitt, X. Fu, L. Thomson, P. L. Fox, et al. 2004.Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114: 529-541.
21. Carr, A. C., M. C. Myzak, R. Stocker, M. R. McCall, and B. Frei. 2000. Myeloperoxidase binds to low-density lipoprotein: potential implications for atherosclerosis. FEBS Lett. 487: 176-180.
22. Yang, C. Y., Z. W. Gu, M. Yang, S. N. Lin, A. J. Garcia-Prats, L. K. Rogers, S. E. Welty, and C. V. Smith. 1999. Selective modification of apoB-100 in the oxidation of low density lipoproteins by myeloperoxidase in vitro. J. Lipid Res. 40: 686-698.
23. Sokolov, A. V., A. V. Chekanov, V. A. Kostevich, D. V. Aksenov, V. B. Vasilyev, and O. M. Panasenko. 2011. Revealing binding sites for myeloperoxidase on the surface of human low density lipoproteins. Chem. Phys. Lipids. 164: 49-53.
24. Yang, C., J. Wang, A. N. Krutchinsky, B. T. Chait, J. D. Morrisett, and C. V. Smith. 2001. Selective oxidation in vitro by myeloperoxidase of the N-terminal amine in apolipoprotein B-100. J. Lipid Res. 42: 1891-1896.
25. Vaes, M., K. Zouaoui Boudjeltia, P. Van Antwerpen, S. Babar, F. Deger, J. Neve, M. Vanhaerverbeek, and J. Ducobu. 2006. Low-density lipoprotein oxidation by myeloperoxidase occurs in the blood circulation during hemodialysis (Abstract). Atheroscler. Suppl. 7: 525.
26. Moguilevsky, N., L. Garcia-Quintana, A. Jacquet, C. Tournay, L. Fabry, L. Pierard, and A. Bollen. 1991. Structural and biological properties of human recombinant myeloperoxidase produced by Chinese hamster ovary cell lines. Eur. J. Biochem. 197: 605-614.
27. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
28. Peterson, G. L. 1977. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem. 83: 346-356.
29. Kettle, A. J., and C. C. Winterbourn. 1988. The mechanism of myeloperoxidase-dependent chlorination of monochlorodimedon. Biochim. Biophys. Acta. 957: 185-191.
30. Van Antwerpen, P., P. Moreau, K. Zouaoui Boudjeltia, S. Babar, F. Dufrasne, N. Moguilevsky, M. Vanhaeverbeek, J. Ducobu, and J. Neve. 2008. Development and validation of a screening procedure for the assessment of inhibition using a recombinant enzyme. Talanta. 75: 503-510.
31. Delporte, C., P. Van Antwerpen, K. Zouaoui Boudjeltia, C. Noyon, F. Abts, F. Metral, L. Vanhamme, F. Reye, A. Rousseau, M. Vanhaeverbeek, et al. 2011. Optimization of apolipoprotein-B-100 sequence coverage by liquid chromatography-tandem mass spectrometry for the future study of its posttranslational modifications. Anal. Biochem. 411: 129-138.
32. Furtmüller, P. G., W. Jantschko, G. Regelsberger, C. Jakopitsch, J. Arnhold, and C. Obinger. 2002. Reaction of lactoperoxidase compound I with halides and thiocyanate. Biochemistry. 41: 11895-11900.
33. Furtmüller, P. G., M. Zederbauer, W. Jantschko, J. Helm, M. Bogner, C. Jakopitsch, and C. Obinger. 2006. Active site structure and catalytic mechanisms of human peroxidases. Arch. Biochem. Biophys. 445: 199-213.
34. Sokolov, A. V., K. V. Ageeva, O. S. Cherkalina, M. O. Pulina, E. T. Zakharova, V. N. Prozorovskii, D. V. Aksenov, V. B. Vasilyev, and O. M. Panasenko. 2010. Identification and properties of complexes formed by myeloperoxidase with lipoproteins and ceruloplasmin. Chem. Phys. Lipids. 163: 347-355.
35. Temple, A., T. Y. Yen, and S. Gronert. 2006. Identification of specific protein carbonylation sites in model oxidations of human serum albumin. J. Am. Soc. Mass Spectrom. 17: 1172-1180.
36. Sell, D. R., C. M. Strauch, W. Shen, and V. M. Monnier. 2007.2-aminoadipic acid is a marker of protein carbonyl oxidation in the aging human skin: effects of diabetes, renal failure and sepsis. Biochem. J. 404: 269-277.
37. Yang, C., Z. W. Gu, M. Yang, S. N. Lin, G. Siuzdak, and C. V. Smith. 1999. Identification of modified tryptophan residues in apolipoprotein B-100 derived from copper ion-oxidized low-density lipoprotein. Biochemistry. 38: 15903-15908.
38. Himmelfarb, J., M. E. McMenamin, G. Loseto, and J. W. Heinecke. 2001. Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic. Biol. Med. 31: 1163-1169.
39. Delporte, C., T. Franck, C. Noyon, D. Dufour, A. Rousseau, P. Madhoun, J. M. Desmet, D. Serteyn, M. Raes, J. Nortier, et al. 2012. Simultaneous measurement of protein-bound 3-chlorotyrosine and homocitrulline by LC-MS/MS after hydrolysis assisted by microwave: application to the study of myeloperoxidase activity during hemodialysis. Talanta. 99: 603-609.
40. Spickett, C. M., A. Reis, and A. R. Pitt. 2013. Use of narrow masswindow, high-resolution extracted product ion chromatograms for the sensitive and selective identification of protein modifications. Anal. Chem. 85: 4621-4627.
41. Panasenko, O. M., H. Spalteholz, J. Schiller, and J. Arnhold. 2003. Myeloperoxidase-induced formation of chlorohydrins and lysophospholipids from unsaturated phosphatidylcholines. Free Radic. Biol. Med. 34: 553-562.
42. Lessig, J., J. Schiller, J. Arnhold, and B. Fuchs. 2007. Hypochlorous acid-mediated generation of glycerophosphocholine from unsaturated plasmalogen glycerophosphocholine lipids. J. Lipid Res. 48: 1316-1324.
43. Yang, C. Y., T. W. Kim, Q. Pao, L. Chan, R. D. Knapp, A. M. Gotto, Jr., and H. J. Pownall. 1989. Structure and conformational analysis of lipid-associating peptides of apolipoprotein B-100 produced by trypsinolysis. J. Protein Chem. 8: 689-699.
44. Yang, C. Y., Z. W. Gu, S. A. Weng, T. W. Kim, S. H. Chen, H. J. Pownall, P. M. Sharp, S. W. Liu, W. H. Li, A. M. Gotto, Jr., et al. 1989. Structure of apolipoprotein B-100 of human low density lipoproteins. Arteriosclerosis. 9: 96-108.
45. Hamilton, R. T., L. Asatryan, J. T. Nilsen, J. M. Isas, T. K. Gallaher, T. Sawamura, and T. K. Hsiai. 2008. LDL protein nitration: implication for LDL protein unfolding. Arch. Biochem. Biophys. 479: 1-14
46. Levine, R. L., B. S. Berlett, J. Moskovitz, L. Mosoni, and E. R. Stadtman. 1999. Methionine residues may protect proteins from critical oxidative damage. Mech. Ageing Dev. 107: 323-332.
47. Pattison, D. I., and M. J. Davies. 2001. Absolute rate constants for the reaction of hypochlorous acid with protein side chains and peptide bonds. Chem. Res. Toxicol. 14: 1453-1464.
48. Pattison, D. I., M. J. Davies, and C. L. Hawkins. 2012. Reactions and reactivity of myeloperoxidase-derived oxidants: differential biological effects of hypochlorous and hypothiocyanous acids. Free Radic. Res. 46: 975-995.
49. Sokolov, A. V., K. V. Ageeva, M. O. Pulina, O. S. Cherkalina, V. R. Samygina, I. I. Vlasova, O. M. Panasenko, E. T. Zakharova, and V. B. Vasilyev. 2008. Ceruloplasmin and myeloperoxidase in complex affect the enzymatic properties of each other. Free Radic. Res. 42: 989-998.
50. Rutgers, A., P. Heeringa, J. P. Kooman, F. M. van der Sande, and J. W. Cohen Travaert. 2003. Peripheral blood myeloperoxidase activity increases during hemodialysis. Kidney Int. 64: 760.
51. Madhusudhana Rao, A., R. Apoorva, U. Anand, C. V. Anand, and G. Venu. 2012. Effect of hemodialysis on plasma myeloperoxidase activity in end stage renal disease patients. Indian J. Clin. Biochem. 27: 253-258.
52. Borén, J., U. Ekström, B. Ågren, P. Nilsson-Ehle, and T. L. Innerarity. 2001. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J. Biol. Chem. 276: 9214-9218.
53. Rutledge, A. C., Q. Su, and K. Adeli. 2010. Apolipoprotein B100 biogenesis: a complex array of intracellular mechanisms regulating folding, stability, and lipoprotein assembly. Biochem. Cell Biol. 88: 251-267.
54. Pawlak, K., M. Mysliwiec, and D. Pawlak. 2013. Oxidized low-density lipoprotein (oxLDL) plasma levels and oxLDL to LDL ratio-are they real oxidative stress markers in dialyzed patients? Life Sci. 92: 253-258.